by Jose Leal, 5th December 2025
Where should we build the next stage of our work?
This question has been driving my thinking about the Gulf for the past year. As Ophiomics moves from clinical validation into manufacturing and regional deployment, I need to understand not just market sizes or tender processes, but what each country’s fundamental characteristics mean for the types of precision diagnostics most likely to succeed there.
In my last article, I discussed Qatar. I am convinced that its small, integrated health system creates very specific advantages that offer it a place of leadership, both in the Gulf and internationally, in clinical translation and systematic validation. Qatar’s specificity is integration at small scale: a coherent environment for generating evidence that larger, more fragmented systems cannot easily replicate.
But what about Saudi Arabia?
My recent visit to the Global Health Exhibition in Riyadh, and my current participation in the Saudi Biotech Accelerator () program, have clarified something important: this is not a zero-sum game where Gulf states compete with each other for the same role. Instead, they have complementary strengths that, if properly understood and combined, can propel the entire region toward the epicenter of the global diagnostics sector. Any company thinking about moving to the region should consider this.
Saudi Arabia sits at the opposite end of the spectrum from Qatar. Its specificity is scale ,and scale creates a different set of strategic opportunities for precision diagnostics. Not just “bigger market” scale, but the kind of scale that changes what is economically viable, what infrastructure can be justified, and what role a country can play in a regional value chain.
What follows is my assessment of how Saudi Arabia’s scale advantages position it uniquely in the GCC diagnostics landscape and why, for a company like Ophiomics developing precision liver diagnostics, understanding these advantages is not academic, but essential to making the right strategic choices about where and how to build.
1. Commercial Scale: Why Saudi Arabia Is the Gulf Gateway
Let me start with the most practical reality facing any diagnostics company, whether European, Asian, or Gulf-based, trying to establish a regional presence.
The economics are very clear:
- Qatar (3 million people) can validate a diagnostic brilliantly, but cannot generate the volume to sustain manufacturing economics
- UAE (10 million) is too small to justify localized production on its own
- Kuwait, Bahrain, Oman (combined ~8 million) are follow-on markets, not primary targets
- Saudi Arabia (36 million), with centralized procurement, unified clinical guidelines, and a hospital network operating at scale, is where a diagnostic moves from promising pilot to profitable product.
This is not about Saudi being “the biggest market” in the abstract. It is about Saudi being the only market where the economics of regional diagnostics presence actually work.
You can validate in Qatar. But you must scale in Saudi Arabia, or you remain a niche player across fragmented small markets with no path to profitability.
This creates, in my opinion, the only viable path for a Gulf-first strategy: any diagnostics company serious about the GCC must crack Saudi Arabia first. Not because it is the easiest market – regulatory timelines are substantial, tender processes are competitive – but because it is the only market where volume justifies the infrastructure investment that regional presence requires.
In short, from a commercial perspective, Saudi Arabia is not one market among six. It is the market that makes the other five viable.
This commercial reality shapes everything else: manufacturing decisions, regulatory strategy, workforce development. If you cannot make the economics work in Saudi Arabia, you cannot make them work in the Gulf.
2. Military Medicine: The Anchor That Can De-Risk Everything
There is a dimension of Saudi Arabia’s diagnostics opportunity that is rarely discussed openly but explains why the Kingdom will – not might, but will – build domestic manufacturing capacity: military medicine.
Saudi Arabia maintains approximately 250,000 active military personnel across the Army, Navy, Air Force, Air Defense, and National Guard. Add dependents, retirees, and veterans entitled to military healthcare, and you have 500,000+ covered lives.
This is a sovereign healthcare obligation. No country with significant regional security responsibilities wants to depend on imported diagnostics for military medical infrastructure.
The reasons are obvious once stated:
- Supply chain vulnerability in geopolitical or pandemic crises
- Strategic autonomy over diagnostic data and manufacturing processes
- Procurement predictability—military healthcare budgets are multi-year, stable, forward-planned
Look at the GCC numbers:
| Country | Active Military | Covered Lives |
| Saudi Arabia | ~250,000 | 500,000+ |
| UAE | ~65,000 | ~150,000 |
| Others | <50,000 | <100,000 |
Only Saudi Arabia has military healthcare scale sufficient to justify standalone diagnostics manufacturing on strategic autonomy grounds alone.
Here is the critical insight: the scale required to serve such sized military medicine is the same scale required to serve the broader GCC civilian market.
A manufacturing operation capable of supplying Saudi military healthcare can easily be scaled to supply the entire Gulf region. Same capital investment. Same quality systems. Same workforce.
Military medicine is thus not just a market segment. It is the anchor demand that de-risks manufacturing investment. Everything beyond that is upside.
For a diagnostics company evaluating Saudi Arabia, this changes the risk calculation completely. The baseline demand exists independent of tender cycles, policy shifts, or competitive dynamics. Build the capability to serve military medicine, and you have built the capability to serve the region.
No other GCC country can make this claim.
3. A Scale Market That Sets Regional Standards
Saudi Arabia’s 90+ public hospitals under unified governance, national transformation programs, and centralized tender mechanisms create something rare: an environment where validated diagnostics can deploy at population scale.
For diagnostics companies, this is not just another commercial opportunity. It is the reference market for the GCC.
When Saudi physicians and procurement authorities standardize on a diagnostic, the rest of the region obviously pays attention. Adoption here influences pricing benchmarks, demand forecasts, clinical practice patterns across the Gulf.
Where Qatar can excel in systematic validation, Saudi Arabia can excel in creating regional adoption curves.
This is about standard-setting authority. NHS England’s decisions impact Commonwealth health systems. Saudi procurement and clinical adoption decisions will shape what becomes standard of care across the Gulf.
So, for diagnostics companies, Saudi adoption is not just about Saudi revenue. It is about establishing the regional standard that Kuwait, Bahrain, Oman follow.
4. Why Manufacturing at Scale Requires Ecosystems
Modern diagnostics manufacturing cannot be achieved by building one factory and recruiting one team.
It requires multiple specialized roles in coordination:
- Quality assurance experts who understand ISO 13485, IVDR, FDA requirements
- Regulatory affairs professionals navigating SFDA, FDA, CE-IVDR simultaneously
- Manufacturing engineers managing production lines and supply chains
- Clinical affairs specialists designing post-market surveillance
- Biostatisticians handling assay validation data
These roles do not emerge from a single employer. They emerge from an industrial ecosystem where:
- Multiple companies compete for talent
- Universities design curricula to meet industry demand
- Supporting services (contract labs, regulatory consultancies) establish local operations
- Professionals can move between employers without relocating
This is why one factory is not enough. Industrial ecosystems require critical mass. In the GCC, only Saudi Arabia has the scale to support this.
Saudi Arabia already has the foundation from its pharmaceutical sector:
- Spimaco, Tabuk, Jamjoom, Riyadh Pharma have created thousands of quality, regulatory, and operations professionals
- Vision 2030 has explicitly identified biomanufacturing as a national priority
- The industrial workforce exists; the policy commitment to expand it is in place
A diagnostics company entering Saudi Arabia does not need to build an entire training pipeline from scratch. It can recruit from an existing pool who can transition with targeted retraining.
This structural advantage is unique in the GCC.
5. SFDA: Regulatory Credibility as Manufacturing Infrastructure
There is a misunderstanding about regulatory authorities. Many companies view them as gatekeepers, hurdles to clear before selling. This is profoundly misguided. For manufacturing, a strong regulatory authority is an essential enabler.
Diagnostics manufacturing at scale requires quality systems, SOPs, post-market surveillance, traceability that meet international standards. Without a credible regulatory authority to audit, certify, and monitor these systems, no international partner will trust the output.
If you manufacture in a jurisdiction with weak regulatory oversight:
- You cannot export to FDA/EMA markets—your site lacks regulatory credibility
- You cannot attract partnerships with global diagnostics companies unwilling to risk brand reputation
This means that SFDA’s maturity is a strategic asset:
- IMDRF membership and active participation in harmonization
- Alignment with ISO 13485
- Post-market surveillance frameworks
- Transparent registration pathways
- Growing recognition from FDA, EMA through cooperation agreements
A diagnostics company manufacturing in Saudi Arabia under SFDA oversight can claim internationally recognized regulatory compliance. This is not just about Saudi market access. It is about making Saudi-manufactured diagnostics exportable to the entire GCC, and potentially Europe, Asia, North America.
Moreover, a strong regulator creates competitive pressure on quality. When SFDA conducts regular inspections and enforces GMP compliance, manufacturers cannot cut corners. This raises ecosystem standards.
Vision 2030 provides the industrial incentives. SFDA provides the regulatory credibility. Together, they create a manufacturing environment few emerging markets can match.
6. Diagnostics Within the Broader Biotech Infrastructure
Saudi Arabia’s biotech ambitions extend far beyond diagnostics. Vision 2030 identifies biotechnology as a pillar of economic transformation, with the Saudi Biotech Accelerator focused on vaccines, biologics, cell therapy, gene therapy.
The industrial infrastructure these ambitions require – GMP facilities, regulatory expertise, quality systems, cold chain logistics, specialized workforce, reference laboratories – is the same infrastructure diagnostics manufacturing requires.
Saudi Arabia is already building this foundation to serve all of life sciences, not diagnostics specifically. But diagnostics offer a strategic advantage within this shared infrastructure: faster deployment cycles. Biologics take 10-15 years from discovery to market. Vaccine manufacturing requires massive capital before revenue. Cell and gene therapies remain in early commercialization with uncertain reimbursement. Diagnostics move from development to market, depending on how innovative they are, in 3-5 years, with lower capital requirements and clearer regulatory pathways.
This means diagnostics can generate early wins as Saudi Arabia builds its broader biotech infrastructure, demonstrating manufacturing capability, regulatory competence, commercial viability while longer-cycle biologics programs mature.
In addition, demanding local manufacture is a typical play that markets as large as Saudi can impose, which means that it become plausible to expect an evolution such as that experienced by South Korea:
Phase 1 (2000s): Samsung Biologics, Celltrion started as contract manufacturers—building operational expertise
Phase 2 (2010s): Moved into biosimilars using manufacturing expertise
Phase 3 (2020s): Now developing novel biologics
Manufacturing capability preceded innovation. Infrastructure enabled it. Saudi Arabia is building that infrastructure now for all biotech. Diagnostics can be among the first sectors to demonstrate success, proving the ecosystem works while vaccines and biologics progress through longer timelines.
When Saudi biotech companies commercialize novel vaccines or biologics from the Accelerator, they will manufacture in Saudi Arabia, using infrastructure the entire life sciences sector, including diagnostics, helped build.
7. The Late Acceleration Advantage
Saudi Arabia is the oldest modern state in the GCC, founded in 1932—decades before most neighbors gained independence. Yet it has been more deliberate in executing economic transformation.
Dubai built diversification incrementally over 40 years. Saudi Arabia’s earlier efforts, while ambitious, often lost momentum when oil prices recovered. Vision 2030, launched in 2016, is different: transformation driven by necessity.
This deliberate timing can create advantages:
Learning from regional experience – observing what worked (free zones, logistics) and what proved challenging (real estate over-reliance, workforce gaps)
Scale without legacy constraints – building coordinated infrastructure at scale from the start, not retrofitting incrementally
Political will and capital alignment – Crown Prince Mohammed bin Salman’s direct backing, PIF’s $700+ billion providing coordinated deployment
For diagnostics manufacturing: Saudi can build a modern industrial ecosystem from first principles: SFDA aligned with international standards, manufacturing zones with integrated quality infrastructure, workforce development linked to industry needs.
8. The GCC Value Chain: Complementarity, Not Competition
The GCC is not a series of competing markets but can become a regional value chain.
Qatar’s differentiation, as I perceived it, is the systematic validation and clinical evidence generation through integrated health systems (I examined in my previous article). The UAE’s positioning in this landscape I will address in a forthcoming piece.
Saudi Arabia’s role, today, is clear: manufacturing and scale deployment. The industrial capacity, workforce scale, and anchor demand that make regional diagnostics economically viable.
A European diagnostics company seeking GCC entry needs:
- Robust validation data
- Manufacturing at attractive economics
- Deployment at scale that generates profitability
Saudi Arabia answers (2) and (3). Without this industrial backbone, the region remains a consumer of imported tests. With Saudi manufacturing scale, the Gulf evolves from importer to producer. In time it can also address 1.
9. The Gaps That Need Addressing
Critical capabilities still need development:
Specialized Workforce: Diagnostics needs regulatory, quality, clinical-affairs experts who understand IVDR, FDA, SFDA in detail. Partnerships with European universities for master’s programs; recruitment incentives for mid-career professionals.
Reference Laboratories: National reference labs, proficiency testing, standardized QC infrastructure. A Saudi-based external quality assessment program would immediately reduce friction.
Technology-Transfer Frameworks: Clear guidelines on IP ownership, royalties, confidentiality to accelerate international investment.
Real-World Evidence Infrastructure: National data platforms integrating diagnostic results, outcomes, cost-effectiveness, making Saudi not just a manufacturing hub but a clinical evidence generation hub.
10. What Success Can Look Like by 2030
With focused execution:
- 15–20 localized manufacturing lines
- 3,000–5,000 high-skilled industrial jobs
- 5–8 Saudi-owned diagnostics companies serving regional/global markets
- GCC-wide pricing advantages through local content
- Sovereign supply capability for liver, oncology, chronic disease diagnostics
- GMP infrastructure supporting Biotech Accelerator commercialization
- 3–5 specialized master’s programs in regulatory affairs, quality management
Not just factories. Capability – industrial, regulatory, clinical – anchoring the Gulf’s precision-medicine future.
On Innovation: Scale as the Foundation, Not the Obstacle
I am not claiming that Saudi Arabia cannot innovate in diagnostics. I am claiming something more specific: that innovation will naturally emerge from scale and infrastructure, not from willing it into existence through policy declarations.
The innovation I expect to see will extend beyond individual product breakthroughs. It will manifest in process innovations, such as more efficient manufacturing methods, better quality control systems, novel regulatory pathways. It will expand into techbio applications, such as AI-driven diagnostic algorithms trained on large-scale clinical datasets, computational approaches to assay optimization, data platforms that integrate diagnostic results with outcomes at population scale.
This is how innovation actually works in industrial sectors. It emerges from the friction of solving real operational problems at scale, from the accumulation of technical expertise across multiple organizations, from the competition for talent that drives specialization.
What I find implausible is the expectation of immediate rampant innovation starting from the current state. You cannot skip the infrastructure-building phase and jump directly to breakthrough innovation. The most plausible pathway is: build manufacturing capability → refine operational excellence → accumulate specialized expertise → innovation emerges organically.
I am convinced the leadership of the Kingdom understands this. The evidence is in the investment pattern: hard infrastructure at every level. SFDA regulatory modernization. Manufacturing zones. Workforce development programs. The Saudi Biotech Accelerator focused on long-cycle biologics and vaccines while creating the industrial foundation those ambitions require.
This is not the behavior of a government chasing immediate innovation wins. This is the behavior of a government building the substrate from which innovation becomes possible.
Diagnostics manufacturing is part of that substrate. Not glamorous, not immediately newsworthy, but essential. And within 5-7 years, when that substrate is in place, the innovation will come, not because it was mandated, but because the conditions that enable it finally exist.
The Strategic Choice
Vision 2030 has made healthcare and life sciences a national priority. So the question is no longer whether Saudi Arabia will invest; it is instead where and how fast.
The Kingdom can remain the largest buyer of imported precision-diagnostics; important, but structurally dependent. Or it can become the industrial and deployment backbone of GCC precision medicine:
- Hosting manufacturing that supplies the region
- Setting price and access benchmarks
- Shaping clinical adoption curves
- Building workforce and infrastructure that biotech innovation requires
For diagnostics companies, this is more than a new market; it is a strategic alignment opportunity. For Saudi Arabia, it is a path to global influence in a sector that will define the next 20 years of healthcare.
The diagnostics industry is ready. The question is whether Saudi Arabia will claim this role with the speed and focus it deserves.
Note: This article continues a series examining how each GCC country can claim distinctive territory in precision diagnostics. The first article, on Qatar’s integration and validation opportunity, is available on LinkedIn and at pereiraleal.com, and it follows from the ideas I proposed in my book Precision Diagnostics: A Founder’s Journey. A more detailed briefing covering manufacturing infrastructure, regulatory pathways, and implementation roadmaps will be available for discussion with interested stakeholders.